A Phase 1b Study to Evaluate the Safety of XEN-101
Megadott ok: Study not stopped for safety reasons. Data were reviewed after the first 23 patients had completed scheduled dosing and there was no signal of efficacy for change in body weight. This clinical trial has been determined to be futile.
Key facts
- Where
- Melbourne, AusztráliaSee the site
- Phase
- 1. fázis
Where in Ausztrália
- Nucleus Network Pty LtdMelbourne, AusztráliaNo longer taking part
Trial details
- Who runs it
- Xeno Biosciences
- Trial code
- NCT06417697
- Record updated
- 2024. szeptember 24.
- Original description
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesityRead full original descriptionShow less
A Phase 1b, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Effects of XEN-101 on Safety, Tolerability, and Pharmacodynamics in Subjects with Obesity
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
Inclusion: Male or female, age 18 to 60 years, inclusive, at Screening; Body mass index of 30 to 45 kg/m2; Stable body weight for at least 3 months (i.e., fluctuation of ≤5%); If a female of childbearing potential, must agree to use double barrier contraception (e.g., condom and 1 additional form of adequate contraception) from the date of signing of the ICF, throughout the study, and for 4 weeks after the final dose of study drug. In addition, she must be advised not to donate ova during this period. If a non-sterilized male is sexually active with a female partner of childbearing potential, he must use double barrier contraception from the date of signing of the ICF, throughout the study, and for 8 weeks after the final dose of study drug. In addition, he must be advised not to donate sperm during this period; If a female of childbearing potential, must have a negative pregnancy test at Screening and on Day 1 (baseline); Able to provide informed consent; Willing and able to comply with this protocol and procedures, including feces collection, and be available for the entire duration of the study.
Exclusion: Currently enrolled in another investigational device or drug study, or less than 30 days or 5 times the half-life of the drug candidate (whichever is longer) has passed between Screening for this study and the end of the Treatment Period of the previous investigational device or drug study; Use of anti-obesity medications (e.g., glucagon-like peptide-1 analogues, stimulants, bupropion/naltrexone) within 6 months before Screening; Evidence of clinically significant cardiac, neurologic, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the Investigator's opinion, would compromise the safety of the subject, interfere with the interpretation of the study results, or otherwise preclude subject participation; Positive result for hepatitis B virus surface antigen, hepatitis C virus ribonucleic acid, and human immunodeficiency virus (HIV) antibody at Screening; Laboratory evidence during Screening of T2D, including glycated hemoglobin (HbA1c) ≥6.5% or fasting glucose ≥126 mg/dL (≥7.0 mmol/L); Diagnosed with type 1 diabetes or type 2 diabetes (T2D) (resolution of T2D >3 years before Screening is allowed); Female who is pregnant, nursing, or intends to become pregnant during the study.